A phase IIb trial of MIN 117 in patients with major depressive disorder in USA
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2017
At a glance
- Drugs MIN 117 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Minerva Neurosciences
- 06 Nov 2017 According to a Minerva Neurosciences media release, the company plans to initiate patient recruitment in this trial in early 2018.
- 06 Oct 2016 New trial record
- 26 Sep 2016 According to a Minerva Neurosciences media release, the US FDA has accepted an Investigational New Drug (IND) application to begin testing of MIN-117 in the United States and this trial is expected to begin in 2017.